Gilead Sciences ($GILD) said Tuesday it will acquire Germany-based Tubulis GmbH for up to $5 billion, including $3.15 billion upfront and up to $1.85 billion in milestone payments, as the company expands its oncology pipeline with antibody-drug conjugates.
- The deal includes Tubulis’ ADC platform and pipeline of experimental cancer therapies.
- Lead candidate TUB-040 is in early-stage development for ovarian cancer and non-small cell lung cancer.
- TUB-030 is being studied across multiple solid tumor types.
- The transaction is expected to close in the second quarter of 2026.
- Tubulis will operate as an ADC research organization within Gilead after closing.
- Tubulis has an existing partnership with Bristol-Myers Squibb ($BMY).
Relevant Companies
- Gilead Sciences ($GILD) – Expanding oncology pipeline through ADC acquisition.
- Bristol-Myers Squibb ($BMY) – Existing collaboration with Tubulis on ADC development.
Editor’s Note: This is a developing story. This article may be updated as more detail
